



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA

JENNIFER L. SAAVEDRA, DR.)
MELISSA STRAFFORD, CAROL)
JACQUEZ, and DAVID MATTHEWS, on)
behalf of themselves and all other persons)
similarly situated,)

Plaintiffs,)

v.)

ELI LILLY AND COMPANY, an Indiana)
corporation)

CASE NO. 2:12-cv-9366-SVW (MANx)

ORDER DENYING PLAINTIFFS’
MOTIONS FOR CLASS
CERTIFICATION PURSUANT TO
FEDERAL RULES OF CIVIL
PROCEDURE 23(b)(3) OR 23(c)(4)
[73, 74]

Defendant.

I. INTRODUCTION

This is a putative class action arising from defendant Eli Lilly and Company’s (“Lilly”) alleged misrepresentations regarding its antidepressant, Cymbalta. Plaintiffs filed this action on October 31, 2012. In their corrected First Amended Complaint (“FAC”), Plaintiffs assert claims under four states’ consumer protection laws. (Dkt. 44.)

Presently before the Court are Plaintiffs’ alternative motions for class certification under Federal Rules of Civil Procedure 23(b)(3) and 23(c)(4). (Dkts. 73 & 74.) For the reasons discussed below, the Court DENIES both motions.

II. FACTUAL AND PROCEDURAL BACKGROUND

Lilly’s antidepressant, Cymbalta, is available only by prescription. (Perahia Decl. ¶ 3.)

1 Since the Food and Drug Administration approved Cymbalta in 2004, Cymbalta’s United States
2 Package Insert (called its “label”) has included a warning about possible discontinuation
3 symptoms. (Hoog Decl. ¶¶ 7, 10.) The warning states that withdrawal symptoms occurred “at a
4 rate greater than or equal to 1% and at a significantly higher rate in duloxetine [Cymbalta’s
5 chemical name]-treated patients compared to those discontinuing from placebo.” (Hoog Decl. ¶
6 12.) This warning has undergone only minor revisions since 2004. (Hoog Decl. ¶ 10.) Plaintiffs
7 Jennifer Saavedra, Melissa Strafford, Carol Jacquez, and David Matthews, Jr. (collectively,
8 “Plaintiffs”) claim that the risk of withdrawal symptoms following Cymbalta is in fact
9 approximately 44%. (Corrected First Amended Complaint (“FAC”) ¶ 30.) Plaintiffs thus claim
10 that in marketing and advertising Cymbalta,¹ Lilly misrepresented the risk of experiencing
11 withdrawal symptoms upon its discontinuation.

12 Plaintiffs filed their FAC on January 10, 2013. (Dkt. 44.) In their FAC, Plaintiffs assert
13 claims under: (1) California’s Consumer Legal Remedies Act (“CLRA”), Cal. Civ Code §§
14 1750, et seq.; (2) California’s Unfair Competition Law (“UCL”), Cal. Bus. & Prof. Code §§
15 17200, et seq.; (3) California’s False Advertising Law (“FAL”), Cal Bus. & Prof. Code §§
16 17500, et seq.; (4) Massachusetts’s Consumer Protection Act, Mass. Gen. Laws Ch. 93A, §§ 1, et
17 seq.; (5) Missouri’s Merchandising Practices Act (“MPA”), Mo. Rev. Stat. §§ 407.010, et seq.;
18 and (6) New York’s Consumer Protection from Deceptive Acts and Practices Law, N.Y. Gen.
19 Bus. Law §§ 349, et seq.²

20 On February 26, 2013, this Court granted Lilly’s motion to dismiss Plaintiffs’ claims for
21 injunctive and declaratory relief for lack of standing. (Dkt 52.) The Court otherwise denied
22 Lilly’s motion to dismiss the complaint. (*Id.*)

23 On March 27, 2013, Lilly moved for summary judgment on the grounds that the learned
24 intermediary doctrine barred relief and that the labels were not misleading to doctors. On June
25 13, 2013, the Court held that the learned intermediary doctrine applies to Plaintiffs’ claims and

26
27 ¹ There is some debate over whether the misrepresentations complained of appeared only in the
28 Cymbalta label or in Lilly’s nationwide advertising materials. *See* (Def’s Opp. Ps’ Motion Class
Cert., at 20.)

² Plaintiffs also assert several individual claims not relevant to the issue of class certification.

1 that Plaintiffs were entitled to additional discovery before a motion for summary judgment
2 would be heard. (Dkt. 72: Order, at 6.) The Court also directed Plaintiffs to move for class
3 certification. (*Id.*) The Court directed the parties to assume for purposes of the motion that
4 plaintiffs will prevail in showing that the warnings given to physicians were inadequate as
5 alleged in the FAC. (*Id.* at 8.)

6 Plaintiffs now move to certify a class, including four subclasses, under Rule 23(b)(3).
7 The class and subclasses are defined as:

8 All natural persons within the Commonwealth of Massachusetts and
9 the States of Missouri, New York, and California who purchased and/or
10 paid for Cymbalta manufactured, distributed, and/or marketed by Lilly from
Cymbalta’s August 2004 launch until the present, divided into the following
four subclasses:

11 (1) A California UCL/FAL/CLRA class of consumers who
12 purchased and/or paid for Cymbalta in California between August
2004 and the present;

13 (2) A Missouri Merchandising Practices Act class of consumers who
14 purchased and/or paid for Cymbalta in Missouri between August
2004 and the present;

15 (3) A New York General Business Law §§ 349-350 class of
16 consumers who purchased and/or paid for Cymbalta in New York
between August 2004 and the present;

17 (4) A Massachusetts General Law Chapter 93A class of consumers
18 who purchased and/or paid for Cymbalta in Massachusetts between
August 2004 and the present

19 (Dkt. 73: Ps’ Mot. Class Cert. Pursuant to Rule 23(b)(3), at 2–3.) Plaintiffs also filed an
20 alternative motion to certify a similarly defined issue class and subclasses under Rule 23(c)(4).

21 (Dkt. 74.) Plaintiffs propose certifying this issue class with respect to “the particular issue of
22 whether Lilly’s omissions regarding Cymbalta were materially misleading under the state laws
23 of Missouri, New York, Massachusetts, and California.” (Dkt. 74: Ps’ Mot. Class Cert. Pursuant
24 to Rule 23(c)(4), at 3–4.)

25 **III. PLAINTIFFS’ MOTION FOR CLASS CERTIFICATION UNDER RULE 23(b)(3)**

26 **A. Legal Standard**

27 A party seeking class certification must satisfy two requirements. *See Zinser v. Accufix*
28 *Research Inst., Inc.*, 253 F.3d 1180, 1186 (9th Cir. 2001), *amended by* 273 F.3d 1266 (9th Cir.
2001). First, the moving party must show that the proposed class meets four criteria: (1) the

1 members of the proposed class must be so numerous that joinder of all claims would be
2 impracticable (“numerosity”); (2) there must be questions of law and fact common to the class
3 (“commonality”); (3) the claims or defenses of the representative parties must be typical of the
4 claims or defenses of absent class members (“typicality”); and (4) the representative parties must
5 fairly and adequately protect the interests of the class (“adequacy”). Fed. R. Civ. P. 23(a).

6 Second, the moving party must demonstrate that the class fulfills the conditions of at
7 least one of the three subdivisions of Rule 23(b). “The party seeking certification bears the
8 burden of showing that each of the four requirements of Rule 23(a) and at least one requirement
9 of Rule 23(b) have been met.” *Zinser*, 253 F.3d at 1186.

10 Plaintiffs assert that the class meets the requirements for Rule 23(b)(3). To qualify for
11 certification under this subsection, a class must satisfy two conditions: (1) common questions of
12 law or fact must “predominate over any questions affecting only individual members,” and (2)
13 class resolution must be “superior to other available methods for the fair and efficient
14 adjudication of the controversy.” Fed. R. Civ. P. 23(b)(3). The predominance requirement is
15 satisfied where common questions comprise a significant portion of the case and can be resolved
16 for all class members in one adjudication. *See In re ConAgra Foods, Inc.*, — F.R.D —, No.
17 CV 11-05379 MMM AGRX, 2014 WL 4104405, at *29 (C.D. Cal. Aug. 1, 2014). Rule
18 23(b)(3)’s predominance requirement also requires the moving party to show that “damages are
19 capable of measurement on a classwide basis.” *Comcast Corp. v. Behrend*, — U.S. —, 133
20 S. Ct. 1426, 1433 (2013). Specifically, this requires plaintiffs to tie their method of proving
21 damages to their theory of liability.³ *Id.*

22 A party seeking to certify a class may not merely rest on his pleadings. Rather, “[a] party
23 seeking class certification must affirmatively demonstrate his compliance with the Rule—that is,
24 he must be prepared to prove that there are *in fact* sufficiently numerous parties, common
25 questions of law or fact, etc.” *Wal-Mart Stores, Inc. v. Dukes*, — U.S. —, 131 S.Ct. 2541,
26

27 ³ Nevertheless, class certification is not defeated solely by the requirement to engage in
28 individualized damages calculations. *Leyva v. Medline Indus. Inc.*, 716 F.3d 510, 514 (9th Cir.
2013) (allowing class certification where individualized damages could readily be calculated from
computerized payroll records).

1 2551 (2011) (emphasis added). Thus, a trial court is expected to engage in a “rigorous analysis”
2 to determine if the moving party has discharged its burden. *Dukes*, 131 S.Ct. at 2551 (quoting
3 *Falcon*, 457 U.S. at 161). This analysis often “will entail some overlap with the merits of the
4 plaintiff’s underlying claim.” *Id.*

5 **B. Application**

6 Because Plaintiffs’ motion for class certification raises more significant problems under
7 Rule 23(b)(3) than under Rule 23(a), the Court first addresses Rule 23(b)(3).

8 **1. Rule 23(b)(3) Requirements**

9 **a. Predominance**

10 Much of the predominance inquiry hinges on Plaintiffs’ unusual theory of injury and
11 damages.

12 **(1) Determining Classwide Damages**

13 Plaintiffs rely on Dr. Joel W. Hay (“Dr. Hay”) to establish their method of proving
14 classwide damages.

15 **(a) *Legal Standard***

16 Federal Rule of Evidence 702 governs the admissibility of expert testimony in the federal
17 courts. Rule 702 provides that:

18 If scientific, technical, or other specialized knowledge will assist the trier of fact
19 to understand the evidence or to determine a fact in issue, a witness qualified as
20 an expert . . . may testify thereto in the form of an opinion or otherwise, if (1)
21 the testimony is based upon sufficient facts or data, (2) the testimony is the
22 product of reliable principles and methods, and (3) the witness has applied the
23 principles and methods reliably to the facts of the case.
24 Fed. R. Evid. 702.

25 In considering expert testimony presented in connection with a motion for class
26 certification, a district court should act as a “gatekeeper” to exclude evidence that doesn’t meet
27 Rule 702’s reliability standard. *Daubert v. Merrill Dow Pharmaceuticals, Inc.*, 509 U.S. 579,
28 591 (1993); *Ellis v. Costco Wholesale Corp.*, 657 F.3d 970, 982 (9th Cir. 2011). Moreover, in
conducting its rigorous analysis of the motion for class certification, the court must go beyond
assessing admissibility under *Daubert*; the court must also assess the persuasiveness of the
evidence. *Ellis*, 657 F.3d at 982–84.

(b) *Application*

At the heart of Plaintiffs' case lies their novel theory of damages. Plaintiffs do not seek damages for personal injuries. Instead, Plaintiffs argue that class members were harmed because they purchased a product that was represented to have a roughly 1% risk of withdrawal side effects but that actually had an approximately 44% risk of withdrawal side effects. Thus, Plaintiffs claim they were injured because the drug as received was worth less than the drug as represented. However, Plaintiffs do not assert that class members were harmed by being overcharged or by being induced to purchase something that they would not have otherwise purchased. Instead, Plaintiffs argue that the harm was in receiving a product that had less *value* than the value of the product as class members expected to receive it. (Suppl. Br. Supp. Ps' Mot. Class Cert., at 4–7.)

Plaintiffs use the term “value” to mean consumer utility—a concept distinct from price. (*Id.* at 5) (describing method of calculating damages and stating that the analysis will “measure the benefit that consumers were *deprived* of by Lilly’s deception” rather than price). According to Plaintiffs, consumer value (also called “utility”) “is the measure of the benefit that consumers believe they will obtain by using or owning a product.” It thus appears that consumer value⁴ is a subjective concept distinct from the fair market value concept commonly used when calculating benefit-of-the-bargain damages. In contrast to consumer value, fair market value is the “price that a seller is willing to accept and a buyer is willing to pay on the open market and in an arm's-length transaction; the point at which supply and demand intersect.”⁵ VALUE, Black's Law Dictionary (9th ed. 2009); *Schwab v. C.I.R.*, 715 F.3d 1169, 1178 (9th Cir. 2013) (quoting Black's Law Dictionary (9th ed. 2009)).

Plaintiffs' theory of injury is distinct from the typical benefit-of-the bargain claim because it focuses only on the demand side of the equation, rather than on the intersection of supply and demand. In other words, Plaintiffs seek to prove injury by proving that each class

⁴ For clarity's sake, “consumer value” is used to refer to the concept of value that Plaintiffs use.

⁵ The Court rejects Plaintiffs' assertion that price is determined only by the seller. (Pls.' Resp. to Def.'s Supp. Submission, at 18.)

1 member received a drug that the average consumer subjectively values less than the average
2 consumer subjectively values the drug he expected to purchase. In contrast, the typical benefit-
3 of-the-bargain claim relies on a difference in fair market value (i.e. the amount that a willing
4 buyer and willing seller would both accept) between the product as represented and the product
5 actually received. As discussed below, this twist on the usual argument causes significant
6 problems. *See Apple, Inc. v. Samsung Electronics Co.*, No. 11-CV-01846-LHK, 2014 WL
7 976898, at *11 (N.D. Cal. Mar. 6, 2014) (rejecting a damages model that failed to provide a way
8 to compare “willingness to pay metrics—which relate only to demand for the patented
9 feature—to the market price of the infringing devices, which reflects the real-world interaction
10 of supply and demand for infringing and noninfringing devices”).

11 Dr. Hay proposes calculating class members’ lost consumer value using conjoint
12 analysis. Conjoint analysis is a statistical technique capable of using survey data to determine
13 how consumers value a product’s individual attributes—often called the market’s willingness to
14 pay. (Dkt. 83: Decl. of Dr. Joel W. Hay (“First Hay Decl.”), ¶ 16). Conjoint analysis “predicts
15 how, on average, all consumers value a particular attribute.” (First Hay Decl., ¶ 18). Dr. Hay
16 claims that he would be able to use conjoint analysis to determine the *relative* value that
17 “consumers place on a drug with a withdrawal risk of ‘greater than or equal to 1%’ compared to
18 a drug whose risk is ‘at least 44%.’” (Dkt. 131: Decl. of Dr. Joel W. Hay (“Third Hay Decl.”), ¶
19 24). This raises the question of how to turn the relative valuation ascertained via conjoint
20 analysis into an absolute valuation to be awarded as damages. Dr. Hay would use the relative
21 value to determine a “refund ratio,” which he would then apply to each class member’s out-of-
22 pocket costs to determine her damages.⁶ (Third Hay Decl., ¶ 25). Thus, if the value of a drug
23 with a 1% withdrawal risk is 30% higher than a drug with a 44% withdrawal risk, then a class
24 member’s damages would be equal to 30% of her out-of-pocket costs. (*Id.*).

25 Even assuming that conjoint analysis can be used to compute the relative value that

26
27 ⁶ In his earlier declarations, Dr. Hay also mentions measuring damages as the dollar amount of
28 consumers’ willingness to pay for a drug with a 1% withdrawal risk rather than a 44% withdrawal
risk, up to the amount of the class member’s out-of-pocket costs. *See* (Second Hays Decl., ¶ 19).
Because neither party focuses on this measure and because it was seemingly abandoned in Dr.
Hay’s third declaration, the Court declines to address it.

1 consumers place on a drug having a lower withdrawal risk (which Lilly disputes), Dr. Hay's
2 proposed measure of damages is highly flawed.

3 First, as discussed above, Dr. Hay's model looks only to the demand side of the market
4 equation. By looking only to consumer demand while ignoring supply, Dr. Hay's method of
5 computing damages converts the lost-expectation theory from an objective evaluation of relative
6 fair market values to a seemingly subjective inquiry of what an average consumer wants. The
7 Court has found no case holding that a consumer may recover based on consumers' willingness
8 to pay irrespective of what would happen in a functioning market (i.e. what could be called
9 sellers' willingness to sell).⁷

10 Second, as Dr. Hay readily admits, the prescription drug market is not an efficiently
11 functioning market. (Third Hay Decl., ¶ 9). Unlike markets for ordinary consumer goods, the
12 prescription drug market is heavily regulated and restricted. (*Id.*). The market is further
13 complicated by insurance plans' (or their absence's) determinative effect on the price that an
14 individual pays. (Suppl. Brief in Supp. Def.'s Opp. to Ps' Motions for Class Cert., at 14.) This
15 price, in turn, relies on prices set by a complex array of contracts between such entities as health
16 plan sponsors, third-party payers, pharmacy benefit managers, retail pharmacy chains, and the
17 drug manufacturer. (*Id.*) Thus, depending on her insurance plan, an individual might pay
18 nothing, a percentage of a "full price" determined by a contract between her insurance provider
19 and another entity, a flat co-payment, or some other "full" price.

20 In an ordinary market, price is a proxy for value. (Third Hay Decl., ¶ 12.) Thus, the
21 price paid for a good that was misrepresented to have a given characteristic can serve as a proxy

22
23 ⁷ Plaintiffs advance *Plubell v. Merck & Co., Inc.*, 289 S.W.3d 707 (Mo. Ct. App. 2009) in support
24 of this proposition. *Plubell* considered consumers' claim that a prescription drug manufacturer
25 violated Missouri's consumer protection statute and held that "because Plaintiffs alleged Vioxx
26 was worth less than the product as represented, they stated an objectively ascertainable loss under
27 the MMPA using the benefit-of-the-bargain rule." *Id.* at 715. However, *Plubell* did not make this
28 statement while considering whether a loss in consumer value (rather than fair market value)
could serve as the measure of damages. Moreover, *Plubell* made this statement while considering
class certification under a state procedural rule that did not allow courts to conduct even a
preliminary inquiry into the merits of plaintiffs' claims. *See id.* at 712. Thus, the court declined
to address defendant's argument that pharmaceutical pricing didn't vary with risk, and stated that
whether plaintiffs could prove their theory of liability was irrelevant. *Id.* at 715, 715 n.6. This is
at odds with the Rule 23 inquiry, which is strict and often overlaps with the merits of plaintiffs'
claims. *See Dukes*, 131 S.Ct. at 2551.

1 for the value of a product with the misstated characteristic. Therefore, applying Dr. Hay's
2 refund ratio to the price paid by consumers in such a market would yield a valid approximation
3 of the value lost due to the misrepresentation. Although the refund ratio determined via conjoint
4 analysis still looks only to the demand side of the equation, applying this ratio to the market
5 price at least tethers it to a functioning market and thus to the product's fair market value.

6 In contrast, the numerous complicating factors in the prescription drug market sever the
7 relationship between price and value. *See In re POM Wonderful LLC*, No. ML 10-02199 DDP
8 RZX, 2014 WL 1225184, at *4 (C.D. Cal. Mar. 25, 2014) (stating that in contrast to an efficient
9 market, in an inefficient market some information is not reflected in an item's price). In other
10 words, a consumer's out-of-pocket cost for a drug is not a proxy for the drug's value to the
11 consumer. *Id.*; (Dkt. 96: Suppl. Decl. of Dr. Joel W. Hay ("Second Hay Decl."), ¶ 13). Thus,
12 class members' out-of-pocket costs are not a proxy for the value of Cymbalta as represented.
13 Therefore, applying the refund ratio to class members' out-of-pocket costs fails to tether the
14 consumers' relative valuations of product features to Cymbalta's fair market value. Instead, it
15 yields an arbitrary amount that is unrelated to the amount of harm incurred by individual class
16 members.

17 Dr. Hay's attempt to overcome this problem fails. Dr. Hay argues that under basic
18 economic principles:

19 [A]ny money spent by the consumer, whether it is the full price or as part of a
20 co-pay, was spent based on an overall valuation of the medication. Since [in
21 this case] that valuation was inflated by a certain percent, i.e. the refund ratio,
22 it makes sense to refund that percent to the consumer.
(Third Hay Decl., ¶ 57c.) While Dr. Hay is correct that a rational consumer would not pay more
23 for the drug than she believes it is worth, he forgets that a rational consumer would surely pay
24 less than she believes the drug is worth. Thus, it does not follow that a consumer who pays a
25 \$20 co-payment believes that the drug is only worth \$20.⁸ Therefore applying the refund ratio to
26 that consumer's co-payment does not yield an accurate approximation of the difference between

27 ⁸ Admittedly, the same could be said with respect to a product's price in a functioning
28 market—that some consumers value the product more highly than the market and are happy to pay
less for the product than they perceive it to be worth. However, this is unproblematic in the
typical benefit-of-the-bargain analysis. Such a theory of liability relies on differences in fair
market value rather than differences in individuals' subjective valuations.

1 the consumer’s subjective valuation of the drug as represented and the drug as actually received.

2 Additionally, Dr. Hay’s model suffers from serious methodological flaws. He proposes
3 conducting a survey in 2014 (or later) to estimate consumers’ valuation of Cymbalta as allegedly
4 represented and as allegedly received. He plans to apply this estimate to harms incurred by class
5 members from 2004 to 2014. Plaintiffs assert that “absent evidence suggesting that consumers
6 have changed their valuation of withdrawal risk itself, changes in the antidepressant marketplace
7 over the last decade—even changes that affect the demand for Cymbalta itself—will not affect
8 the validity of Dr. Hay’s proposed study.” (Supp. Brief in Supp. of Ps’ Motions Class Cert., at
9 26). Lilly points to several changes that it asserts show that consumers have changed their
10 valuation of withdrawal risk, including: new competitive entries, increased awareness of
11 discontinuation side effects, consumer sensitivity to price, changes in the mix of the Cymbalta
12 patient base, and the recent entry of six generic substitutes for Cymbalta. (Yoram Decl., ¶ 32).
13 Dr. Hay refutes these contentions with bare statements of disagreement. *See, e.g.*, (Third Hay
14 Decl., ¶ 60b) (“[S]imply because consumers are more aware that withdrawal risk exists, there is
15 no reason to assume that their valuation of that risk is any different.”). Dr. Hay’s bald assertions
16 are unpersuasive in light of Lilly’s evidence of events that common sense tells are potentially
17 significant to consumer valuation.

18 Finally, and perhaps most importantly, Dr. Hay has yet to design the survey and method
19 he will use in his conjoint analysis. Dr. Hay has not yet collected any data from which he will
20 determine the refund ratio. He has not decided which attributes will be included in his model or
21 whether he will analyze data from each of the four subclass members’ states together or
22 separately. *See* (Third Hay Decl., ¶¶ 15–24.) Dr. Hay admits that only relevant attributes should
23 be included in a conjoint analysis survey. (Third Hay Decl. ¶ 18). However, he has not yet
24 determined that the risk of withdrawal side effects is a relevant and thus appropriate attribute for
25 inclusion in a conjoint analysis of Cymbalta. (Third Hay Decl. ¶ 55) (“As of right now, we
26 cannot state the outcome of this first step [determining the appropriate attributes] of my proposed
27 conjoint analysis, but there is simply no evidence that withdrawal risk is inappropriate as an
28 attribute.”) Thus, Plaintiffs have done worse than not even advancing a reliable method of

1 calculating classwide damages—they have advanced “no damages model at all.” *In re ConAgra*
2 *Foods, Inc.*, 2014 WL 4104405, at *6–7 (refusing to consider expert’s conjoint analysis-based
3 damages model in putative consumer class action because expert failed to identify variables to be
4 included in his model or data in his possession to which the model could be applied).

5 Moreover, given the disconnect between the price paid by a given individual and that
6 individual’s valuation of the product, the Court finds that Dr. Hay’s method is inadequate to
7 calculate damages even on an individual basis. Accordingly, Plaintiffs have failed to show that
8 damages could be “feasibly and efficiently calculated” once liability issues common to the class
9 are decided. *Rahman v. Mott's LLP*, No. 13-CV-03482-SI, 2014 WL 6815779, at *8 (N.D. Cal.
10 Dec. 3, 2014); *accord Lilly v. Jamba Juice Co.*, No. 13-CV-02998-JST, 2014 WL 4652283, at
11 *9–10 (N.D. Cal. Sept. 18, 2014) (same).

12 For all of these reasons, Plaintiffs’ have failed to present a method of calculating
13 damages that is tied to their theory of liability. The Court therefore DECLINES Plaintiff’s
14 motion to certify a damages class under Rule 23(b)(3).

15 (2) Predominance of Other Common Issues

16 “Considering whether ‘questions of law or fact common to class members predominate’
17 begins, of course, with the elements of the underlying cause of action.” *Erica P. John Fund, Inc.*
18 *v. Halliburton Co.*, — U.S. —, 131 S. Ct. 2179, 2184 (2011) (quoting Rule 23(b)(3)).
19 Plaintiffs and Lilly dispute the precise requirements that Plaintiffs must show to prove each of
20 their asserted claims. Much of their dispute centers around the relevant standard of causation
21 that must be satisfied for each claim—specifically whether proof of “but for” causation is
22 required. Nevertheless, the parties apparently agree that each of Plaintiffs’ claims requires proof
23 of some form of causation (which Plaintiffs contend is satisfied by proof of materiality) and of
24 some type of injury. Assuming *arguendo* that each of the relevant laws allows for classwide
25 proof of causation and injury, Plaintiffs still fail to show that classwide proof of causation and
26 injury is appropriate in this case.

27 The causation inquiry is complicated by Plaintiffs’ unique, subjective theory of injury. In
28 the ordinary consumer protection case allowing classwide proof of causation, the theory is: (1) a

1 misrepresentation was made to all class members; (2) a reasonable person would find the
2 misrepresentation important; (3) this important misrepresentation either induced individual class
3 members to buy something they wouldn't have otherwise bought or was absorbed into the
4 market and artificially increased the product's price; and thus, (4) class members were harmed
5 by either buying something they would not have bought but for the misrepresentation or by
6 overpaying for the product due to the artificially increased demand. *See, e.g., Werdebaugh v.*
7 *Blue Diamond Growers*, No. 12-CV-2724-LHK, 2014 WL 2191901, at *1, *12–14 *18–21
8 (N.D. Cal. May 23, 2014) (allowing classwide proof of materiality and reliance for a class of
9 consumers who purchased a product with an allegedly misleading label and who claimed they
10 would not have purchased the product but for the purported misstatements); *Brown v. Hain*
11 *Celestial Grp., Inc.*, No. C 11-03082 LB, 2014 WL 6483216, at *15–18 (N.D. Cal. Nov. 18,
12 2014) (allowing classwide proof of materiality and reliance for class of consumers who
13 purchased a product with an allegedly misleading label and who claimed the label caused them
14 to overpay).

15 Under either of these scenarios, classwide proof of causation makes sense because each
16 class member claims that an objectively material misstatement was made to each class member
17 and caused them each to incur an objectively measurable harm—either paying an inflated fair
18 market price or paying any price at all. In other words, classwide proof of causation is feasible
19 in these circumstances because the same misstatement generally acted in a similar manner on
20 each class member to produce a similar effect.

21 In stark contrast to this typical pattern, Plaintiffs argue that they each purchased
22 something that they expected would be worth more to the average consumer than the thing they
23 actually received—and that this difference in value exists irrespective of price. *See* (Supp. Br. in
24 Support of Pls.' Mot. Class Cert. 5–6) (stating that the amount that Plaintiffs paid for Cymbalta
25 beyond what they claim they should have paid represents “the incrementally greater value that
26 *Plaintiffs* placed on Cymbalta [as a result of the alleged misrepresentation]-it does not represent
27 a higher price”) (emphasis added). As discussed above, Plaintiffs' theory of damages (and thus
28 of injury) is essentially subjective. Because Plaintiffs divorce their injury from price, their

1 asserted injury is akin to subjective disappointment with the product received. Assuming
2 *arguendo* that subjective disappointment is a cognizable harm, the existence and degree of
3 Plaintiffs' claimed injury will differ based on each individual's (or the individual's physician's)
4 consideration of Cymbalta's withdrawal symptom risk relative to Cymbalta's other attributes. In
5 other words, the causal effect of Lilly's alleged misstatements will differ widely between
6 individuals. It is thus inappropriate to assume that because the alleged misstatement would be
7 important to a reasonable person that it must have induced Plaintiffs to purchase Cymbalta or to
8 otherwise incur some objectively measurable harm.

9 Physicians' roles in prescribing Cymbalta further attenuates the causation and materiality
10 inquiries. The importance of the risk of withdrawal side effects to a reasonable physician may
11 differ depending on the severity of the patient's depression or other symptoms treated with
12 Cymbalta. In other words, the reasonable physician can defined only in relation to a patient—an
13 elusive inquiry at best. Even ignoring the learned intermediary doctrine, the extent of a given
14 class member's reliance on her doctor's advice—possibly to the exclusion of all other
15 considerations—will differ depending on the person and her regard and trust in her physician.⁹

16 Plaintiffs attempt to transmute their subjective injury into an objective one by expressing
17 their theory of injury in terms of value to the average consumer. While this measure has some
18 superficial appeal, it is nonetheless inapt. Aside from pointing to the inability to calculate fair
19 market value in the inefficient prescription drug market, Plaintiffs fail to justify using the
20 average consumer's willingness to pay to define injuries classwide. It is unclear to the Court
21 why any individual is harmed when she purchases a product that the average person (but not
22 necessarily the purchaser) subjectively overvalues because of a misrepresentation. It is also not
23 readily apparent that an objectively important misstatement would cause Plaintiffs to pay more
24

25 ⁹ This case is distinguishable from *Krueger v. Wyeth, Inc.*, No. 03CV2496 JAH AJB, 2011 WL
26 8971449 (S.D. Cal. Mar. 30, 2011). In *Krueger* there was no less risky alternative product and
27 plaintiff sought a refund of the entire purchase price (thus obviating the need for "individualized
28 assessment of the drug's value to each class member [or] an individualized assessment of the
proper comparator drug for each class member."). *Id.* at *6. In contrast, there are generic
substitutes available for Cymbalta, as well as other antidepressants. Also, Plaintiffs seek to
recover an individualized assessment of Cymbalta's alleged value rather than their entire purchase
price.

1 than Cymbalta was subjectively worth to them. This argument is akin to relying on proof of the
2 personal injuries incurred by the average car accident victim to show that a particular car
3 accident caused that same amount of harm to a particular victim. Neither argument rests on a
4 sound causal nexus.

5 The Court thus finds that classwide proof of reliance and causation is not appropriate
6 under Plaintiffs' theory of the case. *Cf. In re ConAgra Foods, Inc.*, 2014 WL 4104405, at *30
7 (quoting *Stearns v. Ticketmaster Corp.*, 655 F.3d 1013, 1022-23 (9th Cir. 2011)) (internal
8 quotation marks omitted) ("Citing California law, the Ninth Circuit has held that if a
9 misrepresentation is not material as to all class members, the issue of reliance var[ies] from
10 consumer to consumer and no classwide inference arises."); *Jimenez v. Allstate Ins. Co.*, 765
11 F.3d 1161, 1169 (9th Cir. 2014) (finding the use of statistical sampling among class members to
12 determine liability permissible where the district court accepted a model "capable of leading to a
13 fair determination" of the defendant's liability). For similar reasons, the Court finds that
14 classwide proof of injury is not appropriate under Plaintiffs' theory of their case.

15 Finally, these concerns regarding common proof of causation and injury are compounded
16 by the problems with Plaintiffs' damages model discussed above. Given the Court's finding that
17 no classwide inference of causation is available in this case, Plaintiffs would need to offer some
18 other proof that causation can be established classwide. They claim to do this through Dr. Hay's
19 proposed model. However, the deficiencies in this model render it incapable of showing that
20 causation may be proven classwide. Additionally, the Court is not convinced that causation
21 could be established classwide via experts or class representatives' testimony.

22 For the aforementioned reasons, Plaintiffs failed to establish how causation could be
23 proven on a classwide basis. Thus, they do not satisfy their burden of showing that common
24 questions predominate. *See In re ConAgra Foods, Inc.*, 2014 WL 4104405, at *30 (holding that
25 plaintiffs failed to satisfy predominance requirement where plaintiffs did not demonstrate that
26 reliance and causation were provable on a classwide basis).

27 b. Superiority

28 In determining whether a class action is superior to other available methods of

1 adjudication, courts consider: (1) class members’ interest in “individually controlling the
2 prosecution or defense of separate actions”; (2) the extent and nature of any litigation concerning
3 the controversy already begun by or against class members; (3) the desirability or undesirability
4 of concentrating the litigation of the claims in the particular forum; and (4) the likely difficulties
5 in managing a class action. Rule 23(b)(3)(A)–(D); *Zinser*, 253 F.3d at 1190.

6 Where damages suffered by each class member are not large, the first factor weighs in
7 favor of class certification. *Id.* Here, the damages are not large. Plaintiffs seek only a
8 percentage of their out-of-pocket costs for Cymbalta. For example, Plaintiff Saavedra seeks only
9 a portion of the \$455 of her own money that she alleges she spent on Cymbalta. (Second Hay
10 Decl. ¶ 21). The second factor is neutral: Other individual lawsuits have been filed against Lilly
11 regarding Cymbalta. However, those suits primarily involve personal injuries. The Court is
12 unaware of another consumer protection action regarding Cymbalta that is similar to the case at
13 bar. The third factor favors class treatment. Given the small amount of damages claimed by
14 each putative class member it is desirable to consolidate all claims before one forum. *See In re*
15 *ConAgra Foods, Inc.*, 2014 WL 4104405, at *32.

16 However, the fourth factor—the likely difficulties in managing a class action—strongly
17 counsels against certification. As discussed above, Plaintiffs failed to put forth a reliable and
18 feasible method for calculating classwide damages. *See Leyva*, 716 F.3d at 515 (finding
19 superiority requirement met where plaintiffs showed that individual damages could feasibly be
20 calculated). Given the inability to calculate classwide damages, the need for individualized
21 proof of causation and damages, and the fact-intensive individualized inquiry that will likely be
22 required to show damages, a class action would be unmanageable. These issues are compounded
23 by the enormous size of the putative subclasses. Plaintiffs estimate that there are over 1 million
24 members in the California subclass, over 576,000 members in the New York subclass, over
25 192,000 class members in the Massachusetts subclass, and over 174,000 class members in the
26 Missouri subclass. It would be completely unfeasible to decide each putative class member’s
27 damages (and possibly causation) in one proceeding. Thus, a class action is not the superior
28 method for adjudicating plaintiffs’ claims.

1 For the foregoing reasons, The Court DENIES Plaintiffs' motion to certify a class under
2 Rule 23(b)(3).

3 **IV. PLAINTIFFS' MOTION FOR CLASS CERTIFICATION UNDER RULE 23(C)(4)**

4 In the alternative, Plaintiffs seek certification of an issue class under Federal Rule of
5 Civil Procedure 23(c)(4) with respect to the "issue of whether Lilly's omissions regarding
6 Cymbalta were materially misleading under the . . . [relevant] state laws."

7 Federal Rule of Civil Procedure 23(c)(4) states that "[w]hen appropriate, an action may
8 be brought or maintained as a class action with respect to particular issues." Federal Rule of
9 Civil Procedure 23(c)(4). The Ninth Circuit has approved the use of issue classes where
10 certification under Rule 23(b)(3) is not proper because common questions do not predominate.
11 *See Valentino v. Carter-Wallace, Inc.*, 97 F.3d 1227, 1234 (9th Cir. 1996). However, neither the
12 Ninth Circuit nor the Supreme Court has established when certification of an issue class is
13 appropriate. One problem posed by the certification of issue classes is that this could be used as
14 an end-run around Rule 23(b)(3)'s predominance requirement. *See Castano v. Am. Tobacco Co.*,
15 84 F.3d 734, 745 n.21 (5th Cir. 1996). On the other hand, refusing to certify any issue class
16 under Rule 23(c)(4) unless the predominance requirement was met would render Rule 23(c)(4) a
17 nullity. *See In re Nassau County Strip Search Cases*, 461 F.3d 219, 226 (2d Cir. 2006).

18 Mindful of these competing concerns, the Court finds that certification of an issue class is
19 not proper here. Though materiality is often evaluated on a classwide basis, as discussed above,
20 it is not appropriate to do so here. Moreover, Plaintiffs fail to show that damages can be
21 determined even on an individual basis once liability is decided. Thus certification of an issue
22 class would not advance the resolution of this litigation. *See In re ConAgra Foods, Inc.*, 2014
23 WL 4104405, at *33 (declining to certify a liability issue class because it was unclear that
24 certification of the issue class would fundamentally advance the resolution of the litigation).

25 In *Rahman v. Mott's LLP*, the court refused to certify an issue class under Rule 23(c)(4).
26 The court found that plaintiff failed to show that damages could be calculated on a class-wide
27 basis. *Rahman*, 2014 WL 6815779, at *8. The court acknowledged that the Ninth Circuit seems
28 to have implicitly endorsed other Circuits' approach of allowing the certification of liability-only

1 classes where the plaintiff failed to establish predominance on the damages issue. *Id.* (citing
2 *Jimenez*, 765 F.3d at 1168). The court also distinguished *Lilly v. Jamba Juice Company*.
3 According to *Rahman*, *Jamba Juice* certified a liability class where the plaintiff failed to present
4 any evidence regarding class-wide calculation of damages because “[s]ome of the difficulties in
5 determining individual damages may fall away after liability is determined[.]” *Id.* at *9
6 (alteration in original) (quoting *Jamba Juice*, 2014 WL 4652283, at *11). In contrast to *Jamba*
7 *Juice*, *Rahman*’s claims were already refined by the court’s summary judgment order and
8 *Rahman* had engaged in sufficient discovery to produce the evidence required to show that
9 damages could be proved classwide. *Id.*

10 As in *Rahman* and unlike in *Jamba Juice*, Plaintiffs have already engaged in extensive
11 litigation. Their claims were refined by several of this Court’s Orders (particularly by those
12 regarding Defendant’s motion to dismiss and motion for summary judgment). (Dkts. 52, 72.)
13 The parties have already engaged in substantial discovery, including expert disclosures.
14 Plaintiffs had “ample opportunity to produce evidence necessary to satisfy the requisites of
15 *Comcast* and certify a class as to both liability and damages.” *Rahman*, 2014 WL 6815779, at
16 *9. Plaintiffs nevertheless failed to do so.

17 For the aforementioned reasons, the Court finds that certifying a liability-only issue class
18 under Rule 23(c)(4) will not materially advance this case’s resolution. The Court therefore
19 DECLINES Plaintiffs’ motion to certify an issue class under Rule 23(c)(4).¹⁰

20 **V. ORDER**

21 1. For the aforementioned reasons, the Court DENIES Plaintiffs’ motion to certify a
22 class under Rule 23(b)(3).

23 ///

24 ///

25 ///

26 ///

27 _____
28 ¹⁰ In light of the Court’s conclusions regarding the Rule 23(b)(3) requirements and Rule 23(c)(4),
the Court finds it unnecessary to address the other requirements for class certification.

1 ///

2

3 2. For the aforementioned reasons, the Court DENIES Plaintiffs' motion to certify a
4 class under Rule 23(c)(4).

5 **IT IS SO ORDERED.**

6

7 Dated: December 18, 2014

8



STEPHEN V. WILSON
United States District Judge

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28